PMID- 10897592
OWN - NLM
STAT- MEDLINE
DCOM- 20000926
LR  - 20141120
IS  - 0385-2385 (Print)
IS  - 0385-2385 (Linking)
VI  - 42
IP  - 4
DP  - 2000 May
TI  - [Clinical effects of trandolapril in chronic glomerulonephritis patients with 
      renal insufficiency].
PG  - 333-7
AB  - Trandolapril is a newly developed angiotensin converting enzyme inhibitor (ACEI) 
      whose characteristic is that it undergoes hepatic excretion. ACEI appears to have 
      a specific reno-protective and antiproteinuric role in patients with chronic 
      glomerulonephritis(CGN). Although renally excreted ACEI tend to accumulate and 
      cause side-effects in patients with renal dysfunction, the pharmacokinetics of 
      trandolapril were not affected by renal dysfunction. We compared the effect of 
      other renally excreted ACEI with those of trandolapril on serum creatinine 
      (s-Cr), creatinine clearance(Ccr), proteinuria and total protein(TP) in CGN 
      patients who switched from another ACEI to trandolapril. Twelve hypertensive 
      patients with chronic renal failure(nine males and three females, ranging from 30 
      to 72 years of age) who were treated by other renally excreted ACEIs for long 
      periods(2 to 8 years) with some effects on proteinuria and renal function, were 
      enrolled in the present study. After ACEI therapy, s-Cr had decreased(2.09 to 
      1.80 mg/dl, p < 0.01) as well as proteinuria(1.65 to 0.71 g/day, p < 0.01). A 
      single daily oral dose of 1 mg of trandolapril was administered to these patients 
      regardless of their blood pressure status and renal functions. After change to 
      trandolapril therapy, s-Cr(2.25 to 2.06 mg/dl, p < 0.01) and urinary protein(1.82 
      to 1.34 g/day, p < 0.05) significantly decreased. On the contrary, both Ccr and 
      TP significantly increased at the level of 39.4 to 44.4 ml/min(p < 0.05) and 6.80 
      to 7.02 g/dl (p < 0.01), respectively. No apparent side effects, such as 
      hyperkalemia, hyponatremia, anemia or worsening of the existing renal dysfunction 
      except for coughing, were observed in these patients. Furthermore, none of the 12 
      patients treated with trandolapril required discontinuation of the compound. In 
      conclusion, it was shown from this study that trandolapril is effective for the 
      treatment of hypertensive patients with renal insufficiency irrespective of the 
      original diseases. Thus, it can be envisaged that trandolapril is one of the most 
      appropriate agents compared to other renally excreted ACEI for these patients 
      with renal insufficiency. We recommend the change from other ACEIs to 
      trandolapril, when renal dysfunction might be due to ACEI accumulation.
FAU - Yoshida, A
AU  - Yoshida A
AD  - Division of Nephrology, Nagoya Daini Red Cross Hospital.
FAU - Takeda, A
AU  - Takeda A
FAU - Fukuda, M
AU  - Fukuda M
FAU - Toda, S
AU  - Toda S
FAU - Morozumi, K
AU  - Morozumi K
LA  - jpn
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Jinzo Gakkai Shi
JT  - Nihon Jinzo Gakkai shi
JID - 7505731
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Indoles)
RN  - 1T0N3G9CRC (trandolapril)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics/*therapeutic use
MH  - Antihypertensive Agents/pharmacokinetics/*therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Glomerulonephritis/*drug therapy/physiopathology
MH  - Humans
MH  - Hypertension, Renal/complications
MH  - Indoles/pharmacokinetics/*therapeutic use
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Middle Aged
MH  - Proteinuria
MH  - Renal Insufficiency/*physiopathology
EDAT- 2000/07/18 11:00
MHDA- 2000/09/30 11:01
CRDT- 2000/07/18 11:00
PHST- 2000/07/18 11:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/07/18 11:00 [entrez]
PST - ppublish
SO  - Nihon Jinzo Gakkai Shi. 2000 May;42(4):333-7.